Back to Search Start Over

P423 A new measure to assess quality of care from the patient perspective during the transitional phase

Authors :
A. Sadlo
M. Classen
Sibylle Koletzko
A. Timmer
J. Peplies
H. Bruns
J. Altevers
A. Bergmann
A. Bauer
Source :
Journal of Crohn's and Colitis. 6:S178
Publication Year :
2012
Publisher :
Oxford University Press (OUP), 2012.

Abstract

biologics. This Register will also be basis of a sustainable and comprehensive UK-wide IBD Register. The intention is to incorporate this into the clinical environment so that data can be captured at the point of care. Methods: The first objective was to define the scope and purpose of the Register. To do so, an information group was formed, including representatives from the British Society of Gastroenterology, British Society of Paediatric Gastroenterology Hepatology and Nutrition, IBD Audit group, Crohn’s and Colitis UK, the Primary Care Society for Gastroenterology, the Association of Coloproctology of Great Britain and Ireland, and the Royal College of Physicians in London. It was agreed that the data should answer four main questions about biologics treatment: Appropriateness of use, efficacy, safety and variability of access to biologics. The requirements were refined, and data identified, before the data collection structure and content was described, ensuring that this complied with the Royal College of Physicians’ recordkeeping standards. A generic clinical information system (GeneCIS), currently in use to support clinical care and research, is providing the IT infrastructure. GeneCIS allows data to be collected and used locally, but is remotely hosted and accessed via the secure National NHS Network (N3). Participating hospitals can collect and view their data, but data for national aggregate and analysis is pseudo-ananoymised and held separately. Local outputs such as individual history summaries and outpatient letters will provide support for day-to-day patient care. The Register will start in selected NHS trusts as part of the 3rd UK IBD audit, and incremently rolled out UK-wide. The information requirements, data to be collected, and overall structure have been agreed. Results: Implementation has started in pilot sites within the UK. Conclusions: The Biologics Register will provide a secure and practical data collection tool to assess safety and efficacy.

Details

ISSN :
18739946
Volume :
6
Database :
OpenAIRE
Journal :
Journal of Crohn's and Colitis
Accession number :
edsair.doi...........fc544df66e9b7bc2f2a851cea0ccefe9
Full Text :
https://doi.org/10.1016/s1873-9946(12)60442-5